GANX
Income statement / Annual
Last year (2024), Gain Therapeutics, Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2024, Gain Therapeutics, Inc.'s net income was -$20.41 M.
See Gain Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00 |
$55,180.00 |
$140,108.00 |
$164,994.00 |
$28,881.00 |
$41,301.00 |
$20,609.00 |
| Cost of Revenue |
$84,071.00
|
$80,382.00
|
$64,168.00
|
$7.16 M
|
$2.26 M
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
-$25,202.00
|
$75,940.00
|
-$7.00 M
|
-$2.23 M
|
$41,301.00
|
$20,609.00
|
| Gross Profit Ratio |
0
|
-0.46
|
0.54
|
-42.42
|
-77.22
|
1
|
1
|
| Research and Development Expenses |
$10.79 M
|
$11.52 M
|
$8.38 M
|
$7.16 M
|
$2.26 M
|
$1.59 M
|
$826,880.00
|
| General & Administrative Expenses |
$9.56 M
|
$10.79 M
|
$9.54 M
|
$6.83 M
|
$1.25 M
|
$555,165.00
|
$222,047.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$9.56 M
|
$10.79 M
|
$9.54 M
|
$6.83 M
|
$1.25 M
|
$555,165.00
|
$222,047.00
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$20.35 M
|
$22.31 M
|
$17.92 M
|
$13.99 M
|
$3.51 M
|
$2.14 M
|
$1.05 M
|
| Cost And Expenses |
-$20.35 M
|
$22.31 M
|
$17.92 M
|
$13.99 M
|
$3.51 M
|
$2.14 M
|
$1.05 M
|
| Interest Income |
$0.00
|
$494,234.00
|
$375,357.00
|
$12,495.00
|
$3,637.00
|
$20,540.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$20,540.00
|
$0.00
|
| Depreciation & Amortization |
$84,071.00
|
$83,579.00
|
$64,168.00
|
$15,484.00
|
$9,592.00
|
$2,571.00
|
$741.00
|
| EBITDA |
-$19.79 M |
-$22.17 M |
-$17.78 M |
-$13.82 M |
-$3.47 M |
-$2.10 M |
-$1.03 M |
| EBITDA Ratio |
0
|
-401.77
|
-126.88
|
-83.77
|
-120.14
|
-50.79
|
-49.86
|
| Operating Income Ratio |
0
|
-403.28
|
-126.88
|
-83.8
|
-120.48
|
-50.85
|
-49.9
|
| Total Other Income/Expenses Net |
$476,216.00
|
$64,888.00
|
$279,283.00
|
-$60,425.00
|
-$92,847.00
|
-$86,222.00
|
-$67,441.00
|
| Income Before Tax |
-$19.87 M
|
-$22.19 M
|
-$17.50 M
|
-$13.89 M
|
-$3.57 M
|
-$2.19 M
|
-$1.10 M
|
| Income Before Tax Ratio |
0
|
-402.11
|
-124.89
|
-84.16
|
-123.69
|
-52.94
|
-53.17
|
| Income Tax Expense |
$536,815.00
|
$79,275.00
|
$92,976.00
|
$4,008.00
|
$5,386.00
|
$7,114.00
|
$9,781.00
|
| Net Income |
-$20.41 M
|
-$22.27 M
|
-$17.59 M
|
-$13.89 M
|
-$3.58 M
|
-$2.19 M
|
-$1.11 M
|
| Net Income Ratio |
0
|
-403.54
|
-125.55
|
-84.19
|
-123.88
|
-53.11
|
-53.64
|
| EPS |
-0.89 |
-1.71 |
-1.48 |
-1.37 |
-0.3 |
-0.18 |
-0.19 |
| EPS Diluted |
-0.89 |
-1.71 |
-1.48 |
-1.37 |
-0.3 |
-0.18 |
-0.19 |
| Weighted Average Shares Out |
$22.88 M
|
$13.01 M
|
$11.88 M
|
$10.17 M
|
$11.88 M
|
$11.88 M
|
$5.86 M
|
| Weighted Average Shares Out Diluted |
$22.88 M
|
$13.01 M
|
$11.88 M
|
$10.17 M
|
$11.88 M
|
$11.88 M
|
$5.86 M
|
| Link |
|
|
|
|
|
|
|
